HOLOGIC, INC. (NASDAQ:HOLX) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On August 2, 2017, Hologic, Inc. issued a press release announcing its financial results for the third quarter ended July 1, 2017. A copy of the press release is attached hereto as Exhibit99.1 and is incorporated herein in its entirety by reference.
Limitation on Incorporation by Reference.The information furnished in this Item 2.02, including the press release attached hereto as Exhibit99.1,shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as set forth by specific reference in such a filing.
Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.
Item 2.02 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description |
| 99.1 |
Press release dated August 2, 2017 of Hologic, Inc. announcing its financial results for the third quarter ended July 1, 2017. |
HOLOGIC INC ExhibitEX-99.1 2 v472154_ex99-1.htm EXHIBIT 99.1 Hologic Announces Financial Results for Third Quarter of Fiscal 2017 – Company Posts Revenue of $806.1 Million,…To view the full exhibit click here
About HOLOGIC, INC. (NASDAQ:HOLX)
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
